All In Biotech

NDA 019785 · Shine

Miraluma

Technetium Tc-99m Sestamibi Kit · Injection

Novel

Last checked: Nov 20, 2026Latest source record: Dec 4, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1990

Dec 21, 1990

Approved uses

6

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

476

168 serious, 22 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 10, 2026.

1. INDICATIONS AND USAGE CARDIOLITE® is a myocardial perfusion agent indicated for: detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects) evaluating myocardial function and developing information for use in patient management decisions Myocardial Imaging: CARDIOLITE ® Kit for the Preparation of Technetium Tc99m Sestamibi for Injection, is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. CARDIOLITE ® evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: MIRALUMA ® , Kit for the Preparation of Technetium Tc99m Sestamibi for Injection, is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. MIRALUMA ® is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy.

Mechanism: Technetium Tc99m Sestamibi is a cationic Tc99m complex which has been found to accumulate in viable myocardial tissue in a manner analogous to that of thallous chloride Tl-201. Scintigraphic images obtained in humans after the intravenous administration of the drug have been comparable to those obtained with thallous chloride Tl-201 in normal and abnormal myocardial tissue. Animal studies have shown that myocardial uptake is not blocked when the sodium pump mechanism is inhibited. Although studies of subcellular fractionation and electron micrographic analysis of heart cell aggregates suggest...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 30, 2008 Supplement 18 · Efficacy Summary ReviewLabelLetter
  • May 23, 1997 Supplement 6 · Efficacy
  • Dec 14, 1995 Supplement 4 · Efficacy
  • Dec 14, 1995 Supplement 5 · Efficacy
  • Sep 9, 1992 Supplement 2 · Efficacy
  • Dec 21, 1990 Original approval · Type 1 - New Molecular Entity
2 products under this application
  • MIRALUMA · TECHNETIUM TC-99M SESTAMIBI KIT N/A · INJECTABLE, INJECTION · Discontinued
  • CARDIOLITE · TECHNETIUM TC-99M SESTAMIBI KIT N/A · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Sestamibi Kit" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective94
  • nausea46
  • product preparation error39
  • rash36
  • dyspnoea34
  • urticaria32
  • dizziness29
  • headache27
  • chest pain24
  • vomiting21
  • cough18
  • anxiety16

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200434
200546
200637
200737
200856
20096
20102
201112
20129
20132
20141
201510
201611
201720
201821
201914
20208
20218
202225
202315
202426
202542
202634

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Shine · Also marketed as Cardiolite

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.